09:00 AM EDT, 06/30/2025 (MT Newswires) -- Oncolytics Biotech ( ONCY ) , a clinical-stage company specializing in immunotherapy for oncology, said Monday that it appointed Andrew Aromando as chief business officer.

Aromando has more than 30 years of experience in the life sciences industry and most recently served as chief operating officer of Ambrx Biopharma, Oncolytics said.

Oncolytics' share price gained 6% on Friday to $1.04 on the CSE.